6

result(s)

Word(s)
Publication type
Policy area
Keyword
Date

Biodiversity, nature and soil

01-11-2017

The 1992 UN Conference on the Environment and Development marked a major step forward for the conservation of biodiversity and the protection of nature thanks to the adoption of the Convention on Biological Diversity. In 2011 the EU committed itself to halting the loss of biodiversity and the degradation of ecosystem services in the EU by 2020. Other objectives set out in the Habitats Directive or the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) remain to ...

The 1992 UN Conference on the Environment and Development marked a major step forward for the conservation of biodiversity and the protection of nature thanks to the adoption of the Convention on Biological Diversity. In 2011 the EU committed itself to halting the loss of biodiversity and the degradation of ecosystem services in the EU by 2020. Other objectives set out in the Habitats Directive or the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) remain to be achieved. Since 1992, LIFE has been the most important financial instrument for the protection of biodiversity in the EU.

Public health

01-11-2017

The Treaty of Lisbon has enhanced the importance of health policy, stipulating that ‘a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities’. This objective is to be achieved through Community support to Member States and by fostering cooperation. Primary responsibility for health protection and, in particular, the healthcare systems continues to lie with the Member States. However, the EU has an important role to play ...

The Treaty of Lisbon has enhanced the importance of health policy, stipulating that ‘a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities’. This objective is to be achieved through Community support to Member States and by fostering cooperation. Primary responsibility for health protection and, in particular, the healthcare systems continues to lie with the Member States. However, the EU has an important role to play in improving public health, preventing and managing diseases, mitigating sources of danger to human health, and harmonising health strategies between Member States. The EU has successfully implemented a comprehensive policy, through the Health Strategy ‘Health for Growth’ and its action programme (2014-2020) and a body of secondary legislation. The current institutional set-up to support implementation includes the Commission’s Directorate-General for Health and Food Safety (DG SANTE), as well as specialised agencies, notably the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA).

Medicines and Medical Devices

01-11-2017

Medicines and medical devices are products subject to the rules of the single market, and therefore the EU holds competency for their authorisation through evaluation and supervision. In order to protect public health, before being placed on the market new pharmaceuticals for human use must be authorised under a centralised procedure by the European Medicines Agency (EMA) and/or in a decentralised manner by national agencies. Medical devices require a detailed regulatory framework for market access ...

Medicines and medical devices are products subject to the rules of the single market, and therefore the EU holds competency for their authorisation through evaluation and supervision. In order to protect public health, before being placed on the market new pharmaceuticals for human use must be authorised under a centralised procedure by the European Medicines Agency (EMA) and/or in a decentralised manner by national agencies. Medical devices require a detailed regulatory framework for market access through private-sector organisations called notified bodies; revisions are ongoing and a new legislative approach will come into force in 2017.

Disease Mongering (Pseudo-Disease Promotion)

15-11-2012

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern ...

Disease mongering is the promotion of pseudo-diseases by the pharmaceutical industry aiming at economic benefit. Medical equipment manufacturers, insurance companies, doctors or patient groups may also use it for monetary gain or influence. It has increased in parallel with society's 'medicalisation' and the growth of the pharmaceutical complex. Due to massive investments in marketing and lobbying, ample use of internet and media, and the emergence of new markets, it is becoming a matter of concern, and policy makers should be aware of its perils and consequences.

Workshop Report on 'Health in All Policies (HiAP)' - Brussels, 25 May 2011

15-08-2011

For many years the health consequences of new legislation have been taken into account during the policy formulation process in areas such as agriculture, environment, food and others. The inclusion of Health in All Policies is now enshrined in the Lisbon Treaty (Art. 168). The aim of the workshop was to present an update on how the system is actually functioning within the different Commission services. Several DGs representatives, led by DG SANCO, made contributions. The case of The Netherlands ...

For many years the health consequences of new legislation have been taken into account during the policy formulation process in areas such as agriculture, environment, food and others. The inclusion of Health in All Policies is now enshrined in the Lisbon Treaty (Art. 168). The aim of the workshop was to present an update on how the system is actually functioning within the different Commission services. Several DGs representatives, led by DG SANCO, made contributions. The case of The Netherlands as an example of how it works in a Member State was also presented.

Note on the Pharmaceutical Package for the EP Information Offices (EPIOs)

16-08-2010

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. ...

The Pharmaceutical Package in this document refers to the initiatives taken by the European Commission under the "Communication on the future of the single market in pharmaceuticals for human use", setting out the EC's vision for the sector. It comprises three pieces of legislation put forward to the European Parliament on different aspects of medicinal products. The proposals cover: information to patients on prescription medicines, pharmacovigilance, and patient safety and falsified medicines. These legislative proposals have a direct impact on public health, as well as connections with internal market and industrial policies. In the European Parliament the Committee on Environment, Public Health and Food Safety-ENVI is leading these reports. The committees on the Internal Market-IMCO and Industry, Research & Energy-ITRE are responsible for opinions. This note provides a general overview of the present situation on public health policy and pharmaceutical products in the EU, taking into account its degree of implementation and impact. The note presents the three proposals from a public health perspective with regards to their present state of advancement inside the legislative process. Finally it mentions the main stakeholders for these subjects. The note includes an annex with the key officials responsible for this policy area in the EU institutions. IP/

Upcoming events

27-09-2021
Turning the tide on cancer: the national parliaments' view on Europe's Cancer Plan
Other event -
BECA
27-09-2021
US trade policy
Hearing -
INTA
27-09-2021
Consumer protection and automated decision-making tools in a modern economy
Hearing -
IMCO

Partners